文献速递特殊人群用药治疗药物监测与药物基因组学

妊娠对囊性纤维化女性ETI药代动力学的影响

Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis.
PubMed 文献 · Br J Clin Pharmacol · 2026-05-25

本研究基于法国国家观察性队列中145例囊性纤维化女性(含14例孕妇)的治疗药物监测数据,利用已发表的ETI成人群体药代动力学模型分析妊娠对ETI药代动力学的影响。结果显示妊娠显著增加tezacaftor(0.97至1.44 L/h)和ivacaftor(9.64至11.36 L/h)的表观清除率,提示全身暴露量降低。结论提出需进一步研究妊娠期剂量调整的必要性。

要点

  • 妊娠显著增加tezacaftor和ivacaftor的表观清除率,降低全身暴露。
  • 需从游离药物浓度和临床有效性角度评估妊娠期剂量调整必要性。
  • 目前尚无妊娠期ETI有效性、安全性或药代动力学的临床试验。

核心结论

  • 妊娠显著增加tezacaftor和ivacaftor的表观清除率,提示全身暴露量降低。
  • tezacaftor和ivacaftor总暴露降低是否影响持续疗效尚待评估。
  • 妊娠期是否需要调整剂量需从药代动力学(游离ETI浓度)和药效学(临床有效性)角度进一步研究。

研究设计与样本

  • 法国国家观察性队列研究,纳入145例囊性纤维化女性,其中14例为孕妇。
  • 共采集294份血浆样本,其中47份来自孕妇,均于常规临床诊疗中采集。
  • 采用同一队列先前发表的ETI成人群体药代动力学模型表征各成分的药代动力学,使用Monolix®软件进行模型开发和评价。

主要发现

  • 妊娠显著增加tezacaftor的表观清除率(0.97至1.44 L/h)。
  • 妊娠显著增加ivacaftor的表观清除率(9.64至11.36 L/h)。
  • 表观清除率增加表明tezacaftor和ivacaftor的全身暴露量降低。

临床怎么用

  • 临床药师应关注妊娠期囊性纤维化女性使用ETI时tezacaftor和ivacaftor暴露量可能降低。
  • 目前尚不明确妊娠期是否需要调整ETI剂量,需结合游离药物浓度和临床有效性个体化评估。

局限性

  • 目前尚无临床试验研究妊娠期ETI的有效性、安全性或药代动力学特征。
  • 妊娠期剂量调整的必要性尚未从游离ETI浓度和临床有效性角度进行评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor-tezacaftor-ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population. To date, no clinical trials have investigated the effectiveness, safety or PK profiles of ETI during pregnancy. Given the significant physiological changes that occur throughout gestation, which can alter drug PK, characterizing how pregnancy impacts ETI exposure represents a key step towards informing appropriate dosing strategies. Therefore, the aim of this analysis was to assess pregnancy effect on ETI PK. METHOD: As part of the French national observational cohort study, therapeutic drug monitoring was performed in 145 wwCF, including 14 pregnant participants. PK profiles for each compound were characterized using the previously published ETI adult population PK model from the same cohort, with model development and evaluation performed using Monolix® software. RESULTS: A total of 294 plasma samples, including 47 collected from pregnant participants, were drawn during routine clinical care. Pregnancy was found to significantly increase the apparent clearance of tezacaftor (0.97 to 1.44 L/h) and of ivacaftor (9.64 to 11.36 L/h), indicating a decrease in systemic exposure. CONCLUSION: These findings raise important questions regarding whether decreased total tezacaftor and ivacaftor exposure may compromise the sustained treatment efficacy. The necessity for dose adjustments during pregnancy remains to be evaluated from a PK (unbound ETI concentrations) and pharmacodynamic (clinical effectiveness) perspective, thus warranting further studies.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Magnas P, Bouazza N, Foissac F, et al. Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis. Br J Clin Pharmacol. 2026. PMID: 42185741. doi:10.1002/bcp.70620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。